Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing

Tom Powles, Director of Barts Cancer Center, shared a post on X:

“Neoadjuvant chemo/nivolumab with adjuvant nivolumab show high DFS (HR 0.58) and high pCR in NSCLC.

23% and 35% didn’t have surgery/adjuvant nivolumab respectively.

Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durvalumab/nivolumab/pembrolizumab) awaited.”

Source: Tom Powles/X